Upadacitinib for the Treatment of Recalcitrant Vulvar Lichen Sclerosus
Courtney M Kenyon1, Jamie W Rhoads2, Margaret M Cocks2
1University of Utah School of Medicine.
Objectives:
Incompletely treated vulvar lichen sclerosus can lead to major complications and reduced quality of life. Limited treatment options beyond super-potent topical steroids are available for these recalcitrant cases.
Methods:
In this descriptive, retrospective case series, 3 female patients ages 36-63 presenting with recalcitrant, biopsy-proven vulvar lichen sclerosus were treated with oral upadacitinib at a dosage of 15 mg daily and monitored at 1-2 month intervals.
Results:
All 3 patients experienced clinical improvement in signs of lichen sclerosus and a decrease in symptom severity with minimal side effects.
Conclusions:
Upadacitinib may be an effective treatment option for recalcitrant vulvar LS. More robust studies are needed to fully evaluate the efficacy and limitations of JAK inhibitors in treating lichen sclerosus.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids


